ImmunityBio is a clinical- and commercial-stage immunotherapy company based in San Diego, California, focused on activating the immune system to treat cancer and infectious diseases. Its flagship product, Anktiva, is approved by the U.S. Food and Drug Administration (FDA) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
After trading below $3 for much of 2025, IBRX shares surged sharply and have recently changed hands near $7.87, with a 52-week range spanning roughly $1.95 to $12.43. That dramatic run has prompted investors to search for the next meaningful milestone, and $15 has emerged as a frequently discussed objective. The level carries both psychological weight as a round number and technical relevance, as it sits just above the prior 52-week high and aligns with several analysts' most optimistic near-term price targets.
ImmunityBio's market capitalization is approximately $8.3 billion, an elevated valuation for a company that remains unprofitable. Revenue has grown quickly from a low base, rising from about $15 million in 2024 to roughly $113 million in 2025, with first-quarter 2026 revenue reported near $44 million. However, the company continues to post substantial net losses and negative free cash flow as it invests in commercialization and clinical development.
The disconnect between a large market value and modest current revenue means the stock's price reflects expectations of future growth rather than present earnings. For the $15 target to be reached, those expectations must continue to be validated through tangible commercial and clinical progress.
The strongest argument for a move toward $15 rests on Anktiva's commercial trajectory and its pipeline expansion. Investors are focused on the FDA's review of a label expansion for Anktiva in bladder cancer, which could meaningfully broaden its addressable patient population. Management has also emphasized international opportunities, including a commercial rollout in Saudi Arabia, that could diversify revenue beyond the U.S. market.
Analysts project revenue growth in the range of 50% annually over the coming years, with several forecasting the company could approach profitability within roughly three years. If Anktiva gains traction across additional oncology indications, the revenue ramp could support a higher valuation and bring the $15 level into view.
Wall Street coverage remains broadly constructive. According to data aggregators, the consensus rating is a Strong Buy or Moderate Buy, with four analysts polled by S&P Global carrying an average 12-month price target of $12.75. Other aggregators tracking seven analysts put the average near $14.20, with a high of $23 and a low of $9. Notably, H.C. Wainwright maintains a $15 target, placing it directly at the level investors are debating.
This spread illustrates both the opportunity and the uncertainty. A $15 target is roughly 90% above recent prices, yet it is already reflected in at least one prominent analyst's model, suggesting the level is considered achievable if execution remains on track rather than purely speculative.
Several factors could keep IBRX from reaching $15. The company's heavy cash burn and limited cash position create ongoing financing risk; additional share issuance could dilute existing holders. Dependence on a single product also concentrates risk, and Anktiva faces competition in the NMIBC space, including alternative treatments such as Adstiladrin.
Regulatory and clinical setbacks are always possible in biotechnology, and label expansions are not guaranteed. A widely noted risk is the company's reliance on its founder, Dr. Patrick Soon-Shiong, whose vision and backing are central to the story. Any negative FDA outcome, slower-than-expected commercial uptake, or broader biotech sector weakness could undermine the bullish thesis.
From a technical analysis perspective, the prior 52-week high near $12.43 represents a key resistance level that would likely need to be cleared before any sustained push toward $15. On the downside, the recent trading range and psychological support near $7, followed by lower zones in the mid-single digits, are levels investors may watch. A decisive breakout above the $12–$12.50 area on strong momentum could signal that the $15 objective is becoming more attainable.
For traders monitoring IBRX and similar names, Tickeron's AI Daily Buy/Sell Signals offer a way to track shifting conditions more efficiently. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior, changing market dynamics, and AI-driven analysis. These signals can help traders spot emerging opportunities, monitor existing positions, and identify changing trends without manually reviewing charts. Exploring the AI Daily Buy/Sell Signals can provide an additional, data-driven perspective for those watching whether IBRX builds toward higher levels.
The question of whether ImmunityBio can reach $15 is best framed as a possibility rather than a certainty. The target is supported by a constructive analyst consensus, rapid revenue growth from a low base, and the prospect of label expansion and international commercialization for Anktiva. At the same time, persistent losses, cash burn, single-product dependence, and execution risk all stand between the current price and that level.
Reaching $15 would likely require sustained commercial momentum, a successful regulatory expansion, and a broader market environment that continues to reward high-growth biotech names. Investors should monitor Anktiva sales trends, FDA decisions, cash position and any financing activity, and whether shares can hold above key technical support while building toward the $12.50 resistance zone.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To IBRX | 1D Price Change % | ||
|---|---|---|---|---|
| IBRX | 100% | +2.46% | ||
| AXON - IBRX | 48% Loosely correlated | +0.10% | ||
| ARRY - IBRX | 41% Loosely correlated | +1.54% | ||
| QTTB - IBRX | 39% Loosely correlated | +3.54% | ||
| AMRN - IBRX | 37% Loosely correlated | -1.71% | ||
| ADCT - IBRX | 35% Loosely correlated | -3.60% | ||
More | ||||